<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284035</url>
  </required_header>
  <id_info>
    <org_study_id>RALAM</org_study_id>
    <secondary_id>2014-003142-27</secondary_id>
    <nct_id>NCT02284035</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Dual Therapy With Raltegravir/Lamivudine</brief_title>
  <acronym>RALAM</acronym>
  <official_title>Pilot 24week Clinical Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Raltegravir/Lamivudine Combination, Replacing Standard Combination Therapy in HIV-infected Pts With Prolonged Virological Suppression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety,
      tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when
      replacing standard combination therapy in HIV-infected patients with prolonged virological
      suppression
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in virological suppression assessed with standard plasma HIV-1 RNA detection</measure>
    <time_frame>24 weeks</time_frame>
    <description>Efficacy in virological suppression assessed with standard plasma HIV-1 RNA detection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy in virological suppression assessed with ultrasensitive HIV-1 RNA detection (limit of detection 1 copy/mL)</measure>
    <time_frame>24 weeks</time_frame>
    <description>efficacy in virological suppression assessed with ultrasensitive HIV-1 RNA detection (limit of detection 1 copy/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in peripheral mononuclear blood cells HIV-1 reservoir</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in insulin resistance (HOMA-IR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Composite measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in body fat composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Composite measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in plasma 25-OH vitamin D levels</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in estimated glomerular filtration rate (CKD-EPI)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Composite measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in CD38</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in IL-6</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in sleep quality (Pittsburgh Sleep Quality Index)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in adherence in both treatment arms (Morisky-Green Test)overall tolerability</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total cholesterol</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HDL cholesterol</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDL cholesterol</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triglycerides</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bone mineral density</measure>
    <time_frame>24 weeks</time_frame>
    <description>DEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urine beta-2-microglobulin</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in HLA-DR</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in high sensitivity C-reactive protein</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mononuclear activation SD-14</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mononuclear activation SD-163</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Group 1 Raltegravir / 3TC (MK0518B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir / 3TC (MK0518B ) (50 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 standard combination therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NNRTI-Based Regimen:
â€¢ EFV/TDF/FTC
PI-Based Regimens:
ATV/r + TDF/FTC or DRV/r + TDF/FTC
INSTI-Based Regimens:
DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC
NNRTI-Based Regimens:
EFV plus ABC/3TC or RPV/TDF/FTC
PI-Based Regimen:
ATV/r plus ABC/3TC
PI-Based Regimens:
DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC
INSTI-Based Regimen:
RAL plus ABC/3TC
And other ART regimens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir/3TC</intervention_name>
    <description>MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.</description>
    <arm_group_label>Group 1 Raltegravir / 3TC (MK0518B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV/TDF/FTC</intervention_name>
    <description>standard combination therapy</description>
    <arm_group_label>Group 2 standard combination therapy</arm_group_label>
    <other_name>NNRTI-Based Regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV/r + TDF/FTC or DRV/r + TDF/FTC</intervention_name>
    <arm_group_label>Group 2 standard combination therapy</arm_group_label>
    <other_name>PI-Based Regimens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC</intervention_name>
    <arm_group_label>Group 2 standard combination therapy</arm_group_label>
    <other_name>INSTI-Based Regimens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV plus ABC/3TC or RPV/TDF/FTC</intervention_name>
    <arm_group_label>Group 2 standard combination therapy</arm_group_label>
    <other_name>NNRTI-Based Regimens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV/r plus ABC/3TC</intervention_name>
    <arm_group_label>Group 2 standard combination therapy</arm_group_label>
    <other_name>PI-Based Regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC</intervention_name>
    <arm_group_label>Group 2 standard combination therapy</arm_group_label>
    <other_name>PI-Based Regimens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAL plus ABC/3TC</intervention_name>
    <arm_group_label>Group 2 standard combination therapy</arm_group_label>
    <other_name>INSTI-Based Regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other ART regimens</intervention_name>
    <arm_group_label>Group 2 standard combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eligible patients will be males or females at least 18 years of age. Women of
             childbearing potential must have a negative pregnancy test within 10 days prior to
             randomization into the study.

          2. Patients seropositive for HIV-1 using standard diagnostic criteria.

          3. Patients virologically suppressed during at least 12 months prior to inclusion (viral
             load &lt;50 copies/mL).

          4. Patients on combination antiretroviral therapy (at least 2 antiretroviral drugs) for
             at least 12 months before being randomized in this study.

          5. Patients who are clinically stable in the opinion of the investigator at study entry
             (clinical status and chronic medication must not have not been modified at least 14
             days prior to randomization).

          6. Patients who have signed informed consent to participate in the study.

        Exclusion Criteria:

          1. Pregnancy, lactation, or planned pregnancy during the study period.

          2. Previous failure to an integrase inhibitor-containing regimen.

          3. Previous failure to a 3TC or FTC-containing regimen.

          4. Resistance mutations to 3TC or integrase inhibitor if any resistance test had been
             previously performed.

          5. Any disease or history of disease which, in the opinion of the investigator, might
             confound the results of the study or pose additional risk to patient treatment.

          6. Chronic hepatitis B.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esteban Martinez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esteban Martinez, MD PhD</last_name>
    <phone>+34932275400</phone>
    <phone_ext>3310</phone_ext>
    <email>estebanm@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Albert Arnaiz, MD</last_name>
      <phone>932279838</phone>
      <email>jaarnaiz@clinic.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>Head Clinical Trials Unit</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 10, 2017</submitted>
    <returned>September 7, 2017</returned>
    <submitted>December 12, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

